Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease

Journal of the American Society of Nephrology

Volumn 17, Issue 6, 2006, Pages 1604-1614

  Omori, Sayu ^a   Hida, Mariko ^a   Fujita, Hisayo ^a   Takahashi, Hisahide ^b   Tanimura, Susumu ^c   Kohno, Michiaki ^c   Awazu, Midori ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; FLUID INTAKE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE; MOUSE; NEWBORN; NONHUMAN; OSMOLALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 33646948499     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004090800     Document Type: Article

References (38)

1. Schaeffer HJ, Weber MJ: Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444, 1999
2. Kumar S, Boehm J, Lee JC: p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726, 2003
3. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252, 2000
4. Omori S, Hida M, Ishikura K, Kuramochi S, Awazu M: Expression of mitogen-activated protein kinase family in rat renal development. Kidney Int 58: 27-37, 2000
5. Hida M, Omori S, Awazu M: ERK and p38 MAP kinase are required for rat renal development. Kidney Int 61: 1252-1262, 2002
6. Omori S, Fukuzawa R, Hida M, Awazu M: Expression of mitogen-activated protein kinases in human renal dysplasia. Kidney Int 61: 899-906, 2002
7. Nadasdy T, Laszik Z, Lajoie G, Blick KE, Wheeler DE, Silva FG: Proliferative activity of cyst epithelium in human renal cystic diseases. J Am Soc Nephrol 5: 1462-1468, 1995
8. Winyard PJ, Nauta J, Lirenman DS, Hardman P, Sams VR, Risdon RA, Woolf AS: Deregulation of cell survival in cystic and dysplastic renal development. Kidney Int 49: 135-146, 1996
9. Woo D: Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333: 18-25, 1995
10. Olbrich H, Fliegauf M, Hoefele J, Kispert A, Otto E, Volz A, Wolf MT, Sasmaz G, Trauer U, Reinhardt R, Sudbrak R, Antignac C, Gretz N, Walz G, Schermer B, Benzing T, Hildebrandt F, Omran H: Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet 34: 455-459, 2003
11. Takahashi H, Calvet JP, Dittemore-Hoover D, Yoshida K, Grantham JJ, Gattone VH 2nd: A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol 1: 980-989, 1991
12. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
13. Tanimura S, Asato K, Fujishiro S, Kohno M: Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: Down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun 304: 801-806, 2003
14. Murcia NS, Sweeney WE Jr, Avner ED: New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 55: 1187-1197, 1999
15. Eccles MR: The role of PAX2 in normal and abnormal development of the urinary tract. Pediatr Nephrol 12: 712-720, 1998
16. Torban E, Eccles MR, Favor J, Goodyer PR: PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol 157: 833-842, 2000
17. Ostrom L, Tang MJ, Gruss P, Dressler GR: Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev Biol 219: 250-258, 2000
18. Woolf AS: A molecular and genetic view of human renal and urinary tract malformations. Kidney Int 58: 500-512, 2000
19. Nagao S, Yamaguchi T, Kusaka M, Maser RL, Takahashi H, Cowley BD, Grantham JJ: Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 63: 427-437, 2003
20. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997
21. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000
22. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ: Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003
23. Chatterjee S, Shi WY, Wilson P, Mazumdar A: Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res 37: 1334-1344, 1996
24. Tanner GA, McQuillan PF, Maxwell MR, Keck JK, McAteer JA: An in vitro test of the cell stretch-proliferation hypothesis of renal cyst enlargement. J Am Soc Nephrol 6: 1230-1241, 1995
25. Alexander LD, Alagarsamy S, Douglas JG: Cyclic stretch-induced cPLA2 mediates ERK 1/2 signaling in rabbit proximal tubule cells. Kidney Int 65: 551-563, 2004
26. Li LF, Ouyang B, Choukroun G, Matyal R, Mascarenhas M, Jafari B, Bonventre JV, Force T, Quinn DA: Stretch-induced IL-8 depends on c-Jun NH2-terminal and nuclear factor-kappaB-inducing kinases. Am J Physiol Lung Cell Mol Physiol 285: L464-L475, 2003
27. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816, 1999
28. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL: Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res 84: 505-515, 1999
29. Tanner GA, Tielker MA, Connors BA, Phillips CL, Tanner JA, Evan AP: Atubular glomeruli in a rat model of polycystic kidney disease. Kidney Int 62: 1947-1957, 2002
30. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S: High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 41: 962-971, 2003
31. Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004
32. Grantham JJ: Polycystic kidney disease: Neoplasia in disguise. Am J Kidney Dis 15: 110-116, 1990
33. Hang Le N, van der Wal A, van der Bent P, Lantinga-van Leeuwen IS, Breuning MH, van Dam H, de Heer E, Peters DJ: Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 16: 2724-2731, 2005
34. Parnell SC, Magenheimer BS, Maser RL, Zien CA, Frischauf AM, Calvet JP: Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J Biol Chem 277: 19566-19572, 2002
35. Arnould T, Sellin L, Benzing T, Tsiokas L, Cohen HT, Kim E, Walz G: Cellular activation triggered by the autosomal dominant polycystic kidney disease gene product PKD2. Mol Cell Biol 19: 3423-3434, 1999
36. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004
37. Gile RD, Cowley BD Jr, Gattone VH 2nd, O'Donnell MP, Swan SK, Grantham JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26: 501-507, 1995
38. Nagao S, Yamaguchi T, Kasahara M, Kusaka M, Matsuda J, Ogiso N, Takahashi H, Grantham JJ: Effect of probucol in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 35: 221-226, 2000